Announcement: Cancer Drug Resistance Best Paper Awards
We are excited to announce the launch of the Cancer Drug Resistance (CDR) Best Paper Awards, aimed at recognizing exceptional contributions from authors publishing in our journal. The awards will honor outstanding works in two categories: Best Review Article and Best Research Paper. The Best Review Article category includes two awards for 2023 and two for 2024, while the Best Research Paper category includes one award for each year.
The winners will be selected by the Journal Award Committee, led by our Editor-in-Chief, Professor Godefridus J. Peters.
Both regular submissions and those from Special Issues or Collections are eligible for consideration.
Award Categories:
• Best Review Article (2 for 2023 and 2 for 2024)
• Best Research Paper (1 for 2023 and 1 for 2024)
Selection Criteria:
• Scientific Merit and Impact
Papers should demonstrate solid scientific reasoning, rigor, and evidence-based findings. They should contribute significantly to advancing the understanding of cancer drug resistance, with broad implications for the field. Studies that propose new research directions, provide novel insights, or identify clinical applications will be prioritized.
• Originality and Innovation
Research should present novel ideas, hypotheses, or methodologies that push the boundaries of current knowledge. Original approaches to addressing longstanding challenges in cancer drug resistance, or new conceptual frameworks, will be highly valued.
• Study Design and Methodological Rigor
Papers should feature a strong study design, appropriate experimental techniques, and clear descriptions of data collection and analysis. Novel experimental designs or innovative use of existing techniques to solve complex problems will be key factors for selection.
• Clarity and Quality of Presentation
Articles should be clearly written and well-organized, making complex scientific concepts accessible to a broad readership. High-quality figures, concise arguments, and clear explanations will all be evaluated.
• Citations, Downloads, and Engagement
While not the sole criterion, the number of citations, article downloads, and broader engagement (e.g., media coverage, mention in clinical guidelines) will be considered as indicators of the impact and reach of the paper within the scientific and clinical communities.
• Potential for Translational Impact
Research with clear potential for clinical application or that addresses unmet medical needs in cancer treatment will be strongly considered. Ideally, these papers should bridge the gap between basic research and potential therapeutic strategies.
Additional Considerations:
• For Review Articles: A review article should not only provide a comprehensive and up-to-date synthesis of the literature but also offer new perspectives, frameworks, or conceptual models that help advance the field.
• For Research Papers: Emphasis will be placed on how well the study addresses a critical gap in understanding cancer drug resistance, whether through novel findings or the development of innovative therapeutic strategies.
Prizes:
Each award winner will receive:
• 300 USD
• An electronic certificate of recognition
Timeline:
• The 2023 awards will be announced in June 2025, covering articles published from January 1, 2023, to December 31, 2023.
• The 2024 awards will be announced in January 2026, covering articles published from January 1, 2024, to December 31, 2024.
We encourage all authors who have published their work in Cancer Drug Resistance during these periods to be considered for these prestigious awards.
We look forward to celebrating the outstanding research and contributions that continue to drive progress in the field of cancer drug resistance.
For any inquiries, please contact the editorial office at [email protected].
Editor: Louise Pan
Language Editor: Catherine Yang
Production Editor: Ting Xu
Respectfully Submitted by the Editorial Office of Cancer Drug Resistance
